Drug Resistance Driven by Cancer Stem Cells and Their Niche.
Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. · 2017
Read Drug Resistance Driven by Cancer Stem Cells and Their Niche. by Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5751177.txt.
Introduction
Prieto-Vila and co-authors review how cancer stem cells and their niche drive drug resistance. Cancer stem cells are a small set that can renew themselves and regrow tumors. They resist chemo and radiation far more than other tumor cells. Their sheltered niche adds a second layer of defense.
Neighbor cells in the niche send signals that keep stem cells alive. The matrix around them can block drugs from reaching them. Stem cells also shape the niche back, in a two way loop. The authors argue this joint system should be a drug target. Breaking the loop may stop relapse and spread.
Catalog record
| CREATOR | Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Drug Resistance Driven by Cancer Stem Cells and Their Niche By Marta Prieto-Vila, Ryou-u Takahashi, Wataru Usuba, Isaku Kohama, Takahiro Ochiya Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18122574 ABSTRACT Abstract Drug resistance represents one of the greatest challenges in cancer treatment. Cancer stem cells (CSCs), a subset of cells within the tumor with the potential for self-renewal, differentiation and tumorigenicity, are thought to be the major cause of cancer therapy failure due to their considerable chemo- and radioresistance, resulting in tumor recurrence and eventually metastasis. CSCs are situated in a specialized microenvironment termed the niche, mainly composed of fibroblasts and endothelial, mesenchymal and immune cells, which also play pivotal roles in drug resistance. These neighboring cells promote the molecular signaling pathways required for CSC maintenance and survival and also trigger endogenous drug resistance in CSCs. In addition, tumor niche components such as the extracellular matrix also physically shelter CSCs from therapeutic agents. Interestingly, CSCs contribute directly to the niche in a bilateral feedback loop manner. Here, we review the recent advances in the study of CSCs, the niche and especially their collective contribution to resistance, since increasingly studies suggest that this interaction should be considered as a target for therapeutic strategies. Keywords: cancer stem cells, drug resistance, cancer niche 1. CANCER STEM CELLS 1.1. Introduction Cancer is one of the most devastating diseases worldwide. In 2016, more than 1.5 million people were afflicted in the U.S. Despite recent major advances in understanding the molecular and genetic basis of cancer, more than one third of afflicted people die each year [1]. The leading cause of treatment failure is cancer cells resistance to drug treatment, which leads to tumor recurrence and metastasis. Metastasis remains the cause of more than 90% of cancer-related deaths [2]. Recent studies suggest that cancer stem cells (CSCs) are the main source of this resistance. Tumor-initiating cells or cancer stem cells, as they will be referred into this article, are a small subpopulation of cells within a tumor that retain the capacity for self-renewal and are able to differentiate into the heterogeneous lineages that comprise the tumor. They also possess high tumorigenicity capacity and are thought to be highly resistant to radiation and chemotherapy, making them capable of repopulating a tumor after treatment [3]. CSCs are localized in a specific microenvironment referred to as the niche, which is formed by a variety of cells that promote CSC survival and enhance their characteristics. An in-depth understanding of the biological characteristics of CSCs and in particular their role in drug resistance, is crucial for establishing novel tumor diagnostic and therapeutic strategies. In this article, we review the recent known mechanisms used by CSCs to overcome drug treatment, as well as the role of the niche in CSCs and drug resistance and examine their implications for novel therapeutic strategies. 1.2. CSC History and Origin The concept of CSCs was first described in 1971 by Perce and Wallance, who showed that aggressive undifferentiated cells gave rise to benign, well-differentiated cells in squamous cell carcinoma in vivo [4]. In 1997, John Dick identified a subpopulation of cells in patients with acute myeloid leukemia that was different from the bulk, these leukemic cells exhibited stem-like properties. These cells were described as cancer stem cells [5]. In the following years, CSCs were observed in many kinds of solid cancers, beginning with breast CSCs. Al-Hajj et al. used flow cytometry to identify a small subpopulation of breast cells that displayed the markers CD44+/CD24−/Lin−. As few as 100 cells were able to form tumors in immunocompromised mice [3]. Shortly after, CSCs were also identified in human brain tumors. Singh et al. found a subpopulation of brain tumor cells that exhibited high proliferation, self-renewal and differentiation ability; all of these cells carried the neural stem cell (SC) surface marker CD133 and were described as brain CSCs [6]. CSCs have since been identified in many other solid tumors including prostate, colon and pancreas [7,8,9,10]. CSCs share several features with normal SCs [11]; however, this does not mean that CSCs originate from SCs that become malignant. The origin of CSCs is not yet clear and the CSC state is not static. Various reports describe CSC-enriched populations giving rise to non-CSCs, while non-CSCs can also generate a CSC population [12,13,14]. CSC plasticity within a tumor appears to be dependent on context and environment, as illustrated by a study examining the plasticity of melanoma CSCs. Purified cells expressing JARID1B, a histone demethylase considered to be a melanoma CSC marker, generated JARID1B-negative cells, as expected by the CSC model; however, a single JARID1B-negative cell could also give rise to JARID1B-positive cells [15]. Thus and taking in consideration the plasticity of cancer cells, it seems fair to say that both theories could be asserted. 1.3. Regulators in CSC Phenotype SCs are essential for the maintenance of tissue homeostasis within multicellular organisms. A principal characteristic of SCs is self-renewal, the biological process where, upon cell division, a SC produces one (asymmetric division) or two (symmetric division) daughter cells that retain the capacity for self-renewal. This ensures that a pool of SCs remains available [16]. In the case of asymmetric division, the other resulting cell differentiates to preserve tissue homeostasis. Cancer stem cells are so-named because they share the capacity for long-term self-renewal with SCs. In addition to this characteristic, most of the critical SC pathways including Wnt/B-catenin, Notch and Hedgehog can be found altered in CSCs [17]. Wingless (Wnt)/β-catenin: Upregulation of Wnt/β-catenin signaling has been reported to cause dedifferentiation in both tumor and terminally differentiated cells—such as gastric epithelial cells lines—in which the overexpression of Wnt/β-catenin signaling also induced the generation of fundic gland polyps [18,19]. In head and neck squamous cell carcinoma, Wnt/β-catenin promoted the expression of the stemness markers CD44 and ALDH as well as the drug resistance markers ABCG2 and ABCC4, which signify cisplatin-induced resistance. These changes could be reversed using sFRP4, a Wnt pathway antagonist that not only downregulated drug resistance markers but also reversed the epithelial-to-mesenchymal transition (EMT), as evidenced by the downregulation of N-cadherin and the re-establishment of E-cadherin [20]. Wnt is also a very important signaling pathway for SCs but its targets are currently used as CSC markers. For example, LGR-5 was first described as a SC marker in the intestine but is currently used as a colon cancer CSC marker [21,22]. Sonic Hedgehog: Overexpression of the Hedgehog pathway has been implicated in the maintenance of self-renewal in CSCs from lung squamous cell carcinoma, glioma, colon cancer and breast cancer through regulation of the expression of OCT4, SOX2 and BMI1 [23,24,25,26,27]. Notch: In cancer, Notch signaling is deregulated and promotes self-renewal in breast CSCs [28,29,30] and in oral squamous cell carcinoma by controlling the expression of SLUG and TWIST. Crosstalk with the Wnt and Hedgehog pathways also impacts Notch signaling [31]. Telomerase reactivation: Telomere shortening causes chromosome instability, fusion and ultimately senescence [32]. The long-term self-renewal capacity of tumor cells is due in part to the activation of telomerase a reverse transcriptase enzyme that adds terminal repeats to the 3’ end of telomeres [33,34,35]. For example, one study found telomerase activated in 88–94% of invasive breast carcinoma and none of normal breast tissue [36]. 1.4. Epithelial-to-Mesenchymal